BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10

• 

  Manufacturing

  AMT Designation Takes First Steps Amid Uncertain Benefits

  Cell and gene therapy experts question where the FDA designation fits in an environment that features a range of intersecting regulatory perks.

  October 7, 2025

   · 

  5 min read

   · 

  Nick Paul Taylor
• 

  Drug pricing

  Amgen Hops on DTC Train To Offer Repatha at 60% Discount

  Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.

  October 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail

  Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.

  October 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Pfizer Beat Out Two Other Metsera Suitors for Takeover

  Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.

  October 7, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Business

  BioSpace Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit

  The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.

  October 7, 2025

   · 

  2 min read

   · 

  Angela Gabriel
• 

  IPOs

  UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio

  MapLight laid out the terms of its planned IPO in a regulatory filing on Monday, providing greater detail about what the funds will be used for.

  October 7, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Regulatory

  Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator

  Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.

  October 7, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Tariffs

  Most Life Sciences Companies Not Planning New Investments After Tariffs: Report

  A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”

  October 7, 2025

   · 

  3 min read

   · 

  Dan Samorodnitsky
• Press Releases

  BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

  October 7, 2025

   · 

  6 min read
• Press Releases

  Tosoh Announces 510k Clearance for Highly Anticipated Next-Generation GR01 HbA1c Analyzer: A Fast, Accurate and Efficient Solution for A1c Testing

  October 7, 2025

   · 

  2 min read